NASDAQ:BCPC - Balchem Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $142.50
  • Forecasted Upside: 15.39 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$123.49
▲ +1.78 (1.46%)
1 month | 3 months | 12 months
Get New Balchem Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCPC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCPC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$142.50
▲ +15.39% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Balchem in the last 3 months. The average price target is $142.50, with a high forecast of $145.00 and a low forecast of $140.00. The average price target represents a 15.39% upside from the last price of $123.49.
Buy
The current consensus among 2 contributing investment analysts is to buy stock in Balchem. This rating has held steady since February 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021HC WainwrightBoost Price TargetBuy$126.00 ➝ $145.00Low
i
3/1/2021StephensUpgradeEqual Weight ➝ Overweight$100.00 ➝ $140.00Low
i
2/22/2021HC WainwrightBoost Price TargetBuy$126.00 ➝ $145.00High
i
2/22/2021StephensUpgradeEqual Weight ➝ Overweight$100.00 ➝ $140.00High
i
8/4/2020HC WainwrightBoost Price TargetBuy$104.00 ➝ $126.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
7/9/2020StephensInitiated CoverageEqual Weight$100.00Medium
i
5/4/2020HC WainwrightLower Price TargetBuy$116.00 ➝ $104.00High
i
Rating by Ram Selvaraju at HC Wainwright
2/24/2020HC WainwrightLower Price TargetBuy$122.00 ➝ $116.00High
i
1/31/2020HC WainwrightReiterated RatingBuy$110.00 ➝ $122.00High
i
11/6/2019HC WainwrightReiterated RatingBuy ➝ Positive$95.00 ➝ $110.00High
i
8/5/2019HC WainwrightReiterated RatingBuy$110.00 ➝ $95.00High
i
5/6/2019HC WainwrightReiterated RatingBuy$110.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/6/2019Pivotal ResearchDowngradeBuy ➝ Hold$100.00High
i
2/21/2019Seaport Global SecuritiesInitiated CoverageNeutral ➝ NeutralLow
i
Rating by B. Hundley at Seaport Global Securities
2/5/2019HC WainwrightSet Price TargetBuy$101.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/10/2018HC WainwrightSet Price TargetBuy$101.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/6/2018Pivotal ResearchUpgradeHold ➝ Buy$95.00 ➝ $100.00Low
i
10/16/2018SidotiUpgradeNeutral ➝ Buy$127.00High
i
10/15/2018HC WainwrightSet Price TargetBuy$140.00Low
i
Rating by R. Selvaraju at HC Wainwright
9/25/2018HC WainwrightInitiated CoverageBuy ➝ BuyLow
i
Rating by R. Selvaraju at HC Wainwright
8/3/2018Pivotal ResearchBoost Price TargetHold$85.00 ➝ $95.00High
i
5/7/2018Vertical ResearchDowngradeBuy ➝ HoldMedium
i
5/7/2018Pivotal ResearchUpgradeSell ➝ Hold$85.00Medium
i
11/4/2016Pivotal ResearchDowngradeHold ➝ Sell$65.00 ➝ $60.00N/A
i
8/7/2016Pivotal ResearchReiterated RatingHold$65.00N/A
i
3/8/2016SidotiDowngradeBuy ➝ NeutralN/A
i
(Data available from 3/5/2016 forward)
Balchem logo
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions; and human grade choline nutrients and mineral amino acid chelated products for wellness applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.
Read More

Today's Range

Now: $123.49
$121.05
$123.51

50 Day Range

MA: $117.27
$107.03
$123.69

52 Week Range

Now: $123.49
$78.30
$132.50

Volume

106,223 shs

Average Volume

131,591 shs

Market Capitalization

$4.00 billion

P/E Ratio

48.43

Dividend Yield

0.48%

Beta

0.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Balchem?

The following Wall Street research analysts have issued stock ratings on Balchem in the last year: HC Wainwright, Stephens, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for BCPC.

What is the current price target for Balchem?

2 Wall Street analysts have set twelve-month price targets for Balchem in the last year. Their average twelve-month price target is $142.50, suggesting a possible upside of 17.1%. HC Wainwright has the highest price target set, predicting BCPC will reach $145.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $140.00 for Balchem in the next year.
View the latest price targets for BCPC.

What is the current consensus analyst rating for Balchem?

Balchem currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCPC will outperform the market and that investors should add to their positions of Balchem.
View the latest ratings for BCPC.

What other companies compete with Balchem?

How do I contact Balchem's investor relations team?

Balchem's physical mailing address is 52 Sunrise Park Road, NEW HAMPTON NY, 10958. The basic materials company's listed phone number is 845-326-5600 and its investor relations email address is [email protected] The official website for Balchem is www.balchem.com.